Search results
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and...
KOLR - KSFX Ozarks· 4 days agoProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins ...
In memoriam: Dirk Van Dongen
Politico· 7 days agoThe shift comes as lobbyists fail...of AB Communications Strategies. — Harry Rust is now a research associate at Ervin Graves Strategy Group. — Lisa Wolski...
The Buzz: The Flour Shop shakes it up with new location
The Day· 2 days agoFounders Jon and Hannah Young will be on hand Tuesday, May 21, as The Flour Shop, celebrates a new...
Here’s how Meta’s virtual-reality workout compares to real-life exercise
Fortune via Yahoo Finance· 4 days agoPedante points to people like Curcillo as the reason why Supernatural’s stickiness is so...
Antibiotics wreak havoc on the gut. Can we kill the bad bugs and spare the good ones?
Los Angeles Times· 5 days agoInside every human is a thriving zoo of bacteria, fungi, viruses and other microscopic organisms...
Common low-calorie sweetener linked to heart attack and stroke, study finds
CNN.com· 3 days agoIn 2023, the same researchers found similar results for another low-calorie sweetener called...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D...
Morningstar· 6 days agoIn 2000, it was estimated by the National Multiple Sclerosis Society that around 400,000 Americans had the disease. Although estimates between studies differ, it’s commonly ...
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical...
Benzinga· 7 days ago--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and
